• 1
    Stein JP,Lieskovsky G,Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666675.
  • 2
    Sylvester RJ,van der Meijden AP,Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage ta t1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466477.
  • 3
    Dong H,Strome SE,Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8: 793800.
  • 4
    Hirano F,Kaneko K,Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005; 65: 10891096.
  • 5
    He L,Zhang G,He Y,Zhu H,Zhang H,Feng Z. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res. 2005; 25: 33093313.
  • 6
    Thompson RH,Gillett MD,Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004; 101: 1717417179.
  • 7
    Thompson RH,Kuntz SM,Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006; 66: 33813385.
  • 8
    Dong H,Zhu G,Tamada K,Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5: 13651369.
  • 9
    Reuter VR,Epstein JI,Amin MB,Mostofi FK. A newly illustrated synopsis of the World Health Organization/International Society of Urologic Pathology (WHO/ISUP) consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. J Urol Pathol. 1999; 11: 127.
  • 10
    Sobin SH,Wittekind C. TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002.
  • 11
    Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17: 857872.
  • 12
    Harrell FE. Regression modeling strategies. New York: Springer; 2001.
  • 13
    Madersbacher S,Hochreiter W,Burkhard F, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21 690696.
  • 14
    Mukamel E,Shohat B,Servadio C. Immunological profile of patients with transitional cell carcinoma of the bladder. Br J Urol. 1982; 54: 1115.
  • 15
    Herr HW,Bean MA,Whitmore WFJr. Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture. Cancer Res. 1976; 36: 27542760.
  • 16
    Catalona WJ. Commentary on the immunobiology of bladder cancer. J Urol. 1977; 118(1 Pt 1): 26.
  • 17
    Alexandroff AB,Jackson AM,O'Donnell MA,James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999; 353: 16891694.
  • 18
    Ohigashi Y,Sho M,Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005; 11: 29472953.
  • 19
    Sylvester RJ,van der Meijden A,Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005; 66(6 Suppl 1 ): 90107.
  • 20
    Barber DL,Wherry EJ,Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682687.
  • 21
    Day CL,Kaufmann DE,Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350354.
  • 22
    Freeman GJ,Wherry EJ,Ahmed R,Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006; 203: 22232227.
  • 23
    Iwai Y,Ishida M,Tanaka Y,Okazaki T,Honjo T,Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99: 1229312297.